Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

Hans-Joachim Stemmler,Nadia Harbeck,Isolde Groell de Rivera,Ursula Vehling-Kaiser,Gerhard Rauthe,Wolfgang Abenhardt,A. Artmann,H. Sommer,Hans-Gerd Meerpohl,Marion Kiechle,Volker Heinemann

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

2010

Hans-Joachim Stemmler
Nadia Harbeck
Isolde Groell de Rivera
Ursula Vehling-Kaiser
Gerhard Rauthe
Wolfgang Abenhardt
A. Artmann
H. Sommer
Hans-Gerd Meerpohl
Marion Kiechle
Volker Heinemann

Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to c

Keywords:

Breast cancer
Pathology
Phases of clinical research
Randomization
Cancer
Doxorubicin
Breast disease
Medicine
Docetaxel
Metastatic breast cancer
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations